SAFECAD, The world's first patented retrograde Central Venous Access Device targets a $1.5 B Market, eliminates complications, saves lives, and reduces costs
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free